Overview
IBRX market data
Price History
IBRX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IBRX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right NowBenzinga · Jul 13, 2026, 6:29 PM
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'Benzinga · Jun 17, 2026, 11:55 AM
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price TargetBenzinga · Jun 2, 2026, 10:37 AM
ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung CancerBenzinga · Jun 1, 2026, 5:55 PM
IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens BermanGlobenewswire Inc · May 22, 2026, 5:15 PM
ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete ResponderBenzinga · May 22, 2026, 11:40 AM
ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder CancerBenzinga · May 22, 2026, 11:40 AM
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On WednesdayBenzinga · May 20, 2026, 2:05 PM
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer DrugBenzinga · May 20, 2026, 1:15 PM
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer TherapiesBenzinga · May 19, 2026, 5:15 PM